Precise delivery and controlled release: strategies and advances in TLR7/8 agonist prodrugs for cancer immunotherapy.

Front Immunol · 2026 · PMC12979101 · PMID 41836375

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This finding is highly significant, as it offers a promising new approach to boost the potency and therapeutic utility of IMDQ-based immunotherapies.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.